2 active not recruiting, 2 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Completed 2 |
Follow Bisphosphonate: new trials by email Literature Review of Bisphosphonate trials Research Report on Bisphosphonate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta Romosozumab, Bisphosphonate - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Amgen | 111 | 2024-04-22 | 2026-05-27 |
| Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Bisphosphonate, Setrusumab - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 69 | 2023-06-14 | 2026-10-20 |
| Study in Localized and Disseminated Ewing Sarcoma Zoledronic acid, Busulfan, Treosulfan - Ewing's Sarcoma | Phase 3 | Completed | University Hospital Muenster | 907 | 2009-10-01 | 2019-10-22 |
| Queen's University Investigation of Calcification in Chronic Kidney Disease Bisphosphonate, Placebo - Chronic Kidney Disease | Phase 3 | Completed | Queen's University | 25 | 2008-10-01 | 2015-09-28 |
Osteogenesis Imperfecta (2) · Kidney Failure, Chronic (1) · Neoplasm Metastasis (1) · Renal Insufficiency, Chronic (1) · Sarcoma, Ewing (1) · Vascular Calcification (1)
Amgen (1) · Queen's University (1) · Ultragenyx Pharmaceutical Inc (1) · University Hospital Muenster (1)
Canada (3) · France (2) · Germany (2) · Italy (2) · Poland (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Hungary (1) · Japan (1) · Netherlands (1) · Saudi Arabia (1)
Alan W Craft, Prof Sir MD (1) · Karen E Yeates, Dr (1) · Uta Dirksen, Prof MD (1)
PMID 42470570, PMID 26271204, PMID 31553693, PMID 35427190, PMID 38524902, PMID 39796745
2023 (2), 2008 (1)